Trial Profile
A First-in-Human Randomized, Placebo-controlled, Double-blind, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of LTI-291 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Feb 2021
Price :
$35
*
At a glance
- Drugs LTI-291 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Lysosomal Therapeutics
- 11 Feb 2021 Results published in the British Journal of Clinical Pharmacology
- 03 Mar 2018 Status changed from planning to completed.
- 12 Jan 2017 New trial record